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Identifying disease genes implicated in late-onset neurodegenerative disorders can be challenging due to the
lack of DNA samples from multiple affected family members. To overcome this limitation, Smith et al. (2014)
report in this issue of Neuron the first exome-wide rare variant analysis in unrelated familial amyotrophic
lateral sclerosis (ALS) patients associating TUBA4A with ALS.Amyotrophic lateral sclerosis (ALS) is a
fatal neurodegenerative disease charac-
terized by impairment of both the upper
motor neuron (UMN) and the lower motor
neuron (LMN); its disease course is
relentlessly progressive and most ALS
patients die within a few years due to
respiratory failure. Nonetheless, consid-
erable clinical and genetic variability has
been reported in ALS patients (Turner
et al., 2013). Linkage analyses in
extended ALS families enabled the iden-
tification of genetic loci implicated in ALS
and the discovery of several causal
genes, including superoxide dismutase
1 (SOD1), TAR DNA-binding protein 43
(TARDBP), fused in sarcoma (FUS), and
chromosome 9 open reading frame 72
(C9ORF72). The GGGGCC hexanucleo-
tide repeat expansion in C9ORF72 is
currently the most frequent genetic
cause of ALS as well as frontotemporal
dementia (FTD), a disease that is often
reported as an accompanying feature in
ALS patients and their affected relatives
(DeJesus-Hernandez et al., 2011; Renton
et al., 2011; van Blitterswijk et al., 2012a).
Based on pathological, clinical, and ge-
netic similarities, ALS and FTD are now
thought to represent a continuum of
one broad neurodegenerative disorder
(Ling et al., 2013).
Recently, new technological develop-
ments accelerated the discovery of novel
ALS and/or FTD-associated genes: using
exome sequencing—a technique in which
the coding regions of all genes are
analyzed at once—a mutation in valosin-
containing protein (VCP; p.R191Q) was
identified in an ALS family (Johnson
et al., 2010). In two large ALS families,
exome sequencing also revealed muta-tions in profilin 1 (PFN1; p.C71G and
p.M114T) (Wu et al., 2012). Additionally,
exome sequencing led to the identifica-
tion of matrin 3 mutations (MATR3;
p.F115C) in a family with both ALS and
FTD (Johnson et al., 2014). In families
with multisystem proteinopathy, exome
sequencing revealed mutations in hetero-
geneous nuclear ribonucleoprotein A2B1
and A1 (hnRNPA2B1 and hnRNPA1;
p.D290V and p.D262V) (Kim et al., 2013).
Follow-up experiments that assessed
exome sequencing data of 212 familial
ALS (FALS) patients subsequently re-
sulted in the detection of one hnRNPA1
mutation (p.D262N), suggesting that this
gene might also be involved in the patho-
genesis of ALS. Importantly, while
exome-sequencing was at the basis of
these discoveries, each of these genes
was discovered using a family-based ge-
netic approach, and the variants identified
cosegregatedwith disease. Follow-up ex-
periments were subsequently performed
to strengthen the original reports by the
discovery of additional mutations and/or
by supportive functional data. Other
exome sequencing approaches have
also been employed in ALS, including
sequencing of ALS patients (n = 47) and
both their unaffected parents in order to
search for de novo mutations (Chesi
et al., 2013). This alternative approach re-
vealed the presence of a mutation in
neuronal chromatin remodeling complex
component SS18L1 (also known as
CREST; p.Q388stop). In summary, while
the individual contribution of some of
these novel genes to the genetic etiology
of ALS may be relatively small, each of
these discoveries has contributed to our
current understanding of the causes ofNeuron 84ALS and their underlying pathophysiolog-
ical consequences.
Contrary to what would be expected by
the tremendous progress made in recent
years, the rapidly growing list of ALS
genes is unable to explain the disease in
approximately 50% of FALS patients
and more than 90% of sporadic patients
(SALS), suggesting that additional ALS
genes must exist. In reality, however,
most multigenerational ALS families avail-
able for research purposes have already
been explained by mutations in one of
the known genes, emphasizing the
need for novel genetic approaches. To
this end, a group of researchers headed
by John Landers (Smith et al., 2014)
now report a proof-of-principle study,
which demonstrates that systematic
sequencing of familial, but unrelated,
ALS patients can also be fruitful in ALS.
The group performed exome sequencing
on a unique discovery cohort of 363
index FALS patients obtained through in-
ternational collaborations and control
data of 4,300 individuals (NHLBI’s
Exome Variant Server) and 31 internally
sequenced samples. The size of their pa-
tient cohort is much larger than all previ-
ous exome sequencing studies in ALS
and is particularly impressive given that
less than 10%of ALS patients have a pos-
itive family history.
In the absence of family data, what
strategy did Smith et al. (2014) employ
to determine which of the thousands of
novel or extremely rare genetic variants,
bound to be present in each FALS patient,
is relevant to ALS? Smith et al. (2014) per-
formed a rare variant burden analysis, by
comparing the frequency of genetic vari-
ants observed in each of 12,487 genes, October 22, 2014 ª2014 Elsevier Inc. 241
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The key to their success was in the use
of strict filtering criteria, including only
missense mutations predicted to be
damaging by PolyPhen-2—a software
tool that predicts possible impact of an
amino acid substitution on the structure
and function of a human protein—or mu-
tations resulting in a gain or loss of a
stop codon. They also only included mu-
tations with a minor allele frequency less
than 0.04% to remove potential noise
from common or neutral variants masking
true gene associations. While arbitrary,
these criteria led Smith et al. (2014) to
tubulin, Alpha 4A (TUBA4A), a component
of microtubules, as their top hit and a po-
tential novel ALS disease gene. This is
particularly interesting in light of the
recent discovery of mutations in PFN1
(by the same group) (Wu et al., 2012), as
profilins are one of the most important
actin-binding proteins. After filtering,
they identified four TUBA4A variants in
ALS patients, whereas no damaging vari-
ants were present in control subjects (p =
9.1 3 106, Pcorrected = 0.09). When
including benign variants, five nonsynon-
ymous TUBA4A variants were detected
in patients and three nonsynonymous
TUBA4A variants in controls. Interest-
ingly, all variants identified in ALS patients
were located within a highly conserved re-
gion of TUBA4A encoded by exon 4. The
group also obtained a replication cohort
consisting of 272 index FALS cases and
5,510 internal controls, and those sub-
jects were also sequenced for variants in
exon 4 of TUBA4A. In this replication
cohort, TUBA4A variants were found in
two index cases (one of which did not
segregate with disease) and two controls
(both of which are predicted to be
damaging; p = 1.5 3 102). Importantly,
a combined analysis of the discovery
and replication cohorts led to a statisti-
cally significant overabundance of rare
damaging variants in patients as com-
pared to controls, even after correction
for multiple testing (Pcorrected = 4.2 3
103). Additional sequencing of the entire
coding region in 1,355 sporadic ALS pa-
tients did not identify any mutations in
exon 4, but it did reveal one mutation in
exon 2 thatwas also present in one control
subject and was predicted to be benign.
Microtubules are composed of a heter-
odimer of a- and b-tubulin and are funda-242 Neuron 84, October 22, 2014 ª2014 Elsemental to neuronal morphogenesis and
function. TUBA4A is one of multiple genes
encoding an a-tubulin. Interestingly, mu-
tations in at least seven other tubulin fam-
ily members have been described to
cause neurodevelopmental and neurode-
generative disorders (Tischfield et al.,
2011). Through a panel of in vitro assays,
Smith et al. (2014) suggest that at least a
subset of the TUBA4A variants identified
in ALS patients disrupt microtubule dy-
namics and stability. Transient transfec-
tion of TUBA4A mutants in primary motor
neurons and HEK293 cells revealed an
inability to efficiently form a-/b-tubulin di-
mers in vitro and a decreased incorpora-
tion of some mutants into microtubules.
Studies in COS7 cells also suggested
that TUBA4A mutants inhibited microtu-
bule network assembly and showed that
expression of the mutants impaired the
ability of endogenous TUBA4A protein
to form microtubules, suggesting a
dominant-negative disease mechanism.
Finally, expression of at least one mutant
(p.W407X) resulted in the formation of
numerous small ubiquitinated cyto-
plasmic inclusions analogous to other
ALS-associated mutations; however,
since brain and spinal cord tissue of
TUBA4A mutation carriers was not avail-
able for study, the relevance of these
aggregates in vivo remains unclear.
The study led by John Landers identi-
fied a total of eight TUBA4A variants in
ALS patients (six predicted damaging)
and five variants in controls (two pre-
dicted damaging). One has to realize,
though, that of the six potential damaging
variants observed in patients, at least one
did not segregate with disease (p.K430N)
and another variant (p.A383T) was also
present in an individual of African ancestry
in one of the public databases studied. In
fact, due to the lack of DNA samples from
affected relatives, familial segregation
with disease could only be demonstrated
for two first-degree relatives carrying the
p.T145P mutation and not for any of other
TUBA4A mutations identified in this
study. Moreover, in the absence of any
recurrent mutation across ALS families,
the selection of a representative mutation
for in vivo modeling and characterization
of its functional effect(s) is challenging.
This points to the major limitation of a
burden test as used in this study and
underlines why it is important to bevier Inc.extremely careful in the interpretation of
the effect on ALS risk for individual
TUBA4A variants. While Smith et al.
(2014) have clearly demonstrated that
their approach can be valuable in identi-
fying novel players in ALS disease, and
potential novel therapeutic targets, no
single TUBA4A variant to date can be
considered pathogenic. Actually, it is
likely that the effect of TUBA4A variants
on ALS disease risk span a continuum
from clearly pathogenic mutations, to
mere ALS risk factors and even protective
variants. While Smith et al. (2014) re-
ported that no TUBA4A mutations were
identified in 131 ALS samples with known
mutations in ALS-associated genes, the
current study also cannot rule out the pos-
sibility that the presence of (at least some
of) these TUBA4A variants is insufficient
to develop ALS on its own and that addi-
tional factors are needed to cause dis-
ease. This thought is particularly intriguing
because ALS appears to arise from an
interplay of many factors (e.g., genetic,
developmental, environmental, and age
related) (Turner et al., 2013) and evidence
for an oligogenic basis of ALS has already
been provided (van Blitterswijk et al.,
2012b).
In summary, follow-up studies will be
required to elucidate the role of TUBA4A
in the pathogenesis of ALS. Sequencing
analysis of large numbers of additional
FALS patients, SALS patients, and con-
trols will be needed, not only to provide
additional statistical support for a role of
TUBA4A in ALS but also to systematically
catalog TUBA4A variants, which will
hopefully identify specific recurrent muta-
tions in ALS patients. The role of TUBA4A
in related disorders such as FTD also re-
quires future study, especially since two
of the mutation carriers were diagnosed
with a combination of ALS and FTD
(although they did carry variants pre-
dicted to be benign). Additional data min-
ing of the exomes of the current and
potentially even larger future cohorts of
FALS patients, may also reveal additional
ALS-associated genes. In this regard, it is
important to mention that the strategy
employed in the current study also re-
vealed other strong candidates, including
MATR3, recently identified as causative
for ALS (Johnson et al., 2014). There is
no doubt that exome- and genome-wide
rare variant analyses such as those
Neuron
Previewsdescribed in this pioneering work from
John Landers and his colleagues are
going to drive the identification of novel
ALS genes in the future. Translating
these findings to disease risk for indi-
vidual patients will however be a tremen-
dous challenge and caution should be
taken before any individual variant identi-
fied using this approach can be impli-
cated in ALS.
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Event memories are stored in hippocampal-cortical networks. In this issue of Neuron, two studies, Cowans-
age et al. (2014) and Tanaka et al. (2014), tag active cells duringmemory encoding and optogeneticallymanip-
ulate the activity of these ‘‘engram’’ cells during subsequent recall to reveal how hippocampal and cortical
cell ensembles interact during retrieval.While there is plenty of debate in the
memory field, the classical view is that
memory traces for events are laid down
in cell ensembles across distributed hip-
pocampal-cortical networks. The hippo-
campus is considered necessary, at least
temporarily after encoding, for successful
retrieval of these event memories via
reinstatement of the patterns of activity
within these cortical ensembles. Accord-
ing to this view, the hippocampus con-
tains indices or pointers to cortical cell
assemblies that collectively represent a
given event (e.g., Eichenbaum, 2000).
Observations of retrograde amnesia
following hippocampal damage in humanpatients (such as H.M.), as well as in ex-
perimental animals,providebroadsupport
for this view (Squire et al., 2004). However,
they tell little about how hippocampal
and cortical cell ensembles interact to
support memory retrieval. Two studies
published in the current issue of Neuron,
Cowansage et al. (2014) and Tanaka
et al. (2014), shed light on this interaction.
Both studies used a genetic strategy
to tag active cells at the time of memory
encoding with light-sensitive opsins and
then optogenetically manipulate the activ-
ity of these ‘‘engram’’ cells during retrieval.
In the first study, Tanaka et al. (2014)
used a Fos-driven reporter mouse to tagactive cells as mice learned an associa-
tion between a shock and a context. The
formation and maintenance of contextual
fear memories engages distributed net-
works, and, as expected, training tagged
ensembles of cells throughout the hippo-
campus and cortex. Usually, when mice
return to the original training context,
they exhibit conditioned fear responses,
including freezing behavior, indicating
that they recognize this as the place in
which they previously received a shock.
By expressing the inhibitory opsin (ArchT)
in tagged cells in the CA1 region of the
hippocampus, Tanaka et al. (2014) exam-
ined the impact of silencing engram cells, October 22, 2014 ª2014 Elsevier Inc. 243
